Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260771 | 0.80 | MTNR1A (0.34) | ATML3MBTL1MTNR1AMTNR1BGAA | |
| SCHEMBL446679 | 0.73 | MTNR1A (0.40) | MTNR1AMTNR1BCA4GAACYP1A2 | |
| SCHEMBL43675 | 0.72 | MTNR1A (0.42) | MTNR1AMTNR1BCA4GAACYP1A2 | |
| SCHEMBL4739360 | 0.72 | ATM (0.43) | ATML3MBTL1MTNR1AMTNR1BCA4 | |
| SCHEMBL9353539 | 0.72 | MTNR1A (0.42) | MTNR1AMTNR1BCA4GAACYP1A2 | |
| SCHEMBL7661580 | 0.72 | LTA4H (0.39) | ATML3MBTL1MTNR1AMTNR1BCA4 | |
| SCHEMBL8733234 | 0.72 | CA4 (0.42) | ATML3MBTL1MTNR1AMTNR1BCA4 | |
| SCHEMBL8718949 | 0.70 | ATM (0.40) | ATML3MBTL1MTNR1AMTNR1BCA4 | |
| SCHEMBL11911977 | 0.70 | ATM (0.40) | ATML3MBTL1MTNR1AMTNR1BCA4 | |
| SCHEMBL11022205 | 0.70 | KDM4E (0.40) | ATML3MBTL1MTNR1AMTNR1BCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585755-B1 | METHODS AND COMPOSITIONS FOR THE TANDEM SYNTHESIS OF TWO OR MORE OLIGONULEOTIDES ON THE SAME SOLID SUPPORT | SIGMA ALDRICH CO LLC (US) | 2015-08-05 | — | — | EP | claimed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| US-8618279-B2 | Synthesis of 2′,3′— and 3′,5′—cyclic phosphate mono-and oligonucleotides | CHEMGENES CORPORATION (US) | 2013-12-31 | — | — | US | claimed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| EP-2303905-B1 | CHEMICAL RNA SYNTHESIS METHOD | CENTRE NAT RECH SCIENT (FR) | 2012-11-28 | — | — | EP | claimed |
| US-20110275793-A1 | Chemical RNA Synthesis Method | CHEMGENES CORPORATION | 2011-11-10 | — | — | US | claimed |
| JP-4791043-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-7872121-B2 | Process for the removal of exocyclic base protecting groups | AVECIA BIOTECHNOLOGY, INC. (US) | 2011-01-18 | — | — | US | claimed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20090047712-A1 | Chemically cleavable phosphoramidite linkers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | claimed |
| US-6187914-B1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES USING ELECTROCHEMICALLY LABILE PROTECTING GROUPS WHICH CAN BE REMOVED BY CREATING POTENTIAL DIFFERENCE BETWEEN WORKING ELECTRODE AND COUNTERELECTRODE | CIS BIO INTERNATIONAL (FR) | 2001-02-13 | — | — | US | claimed |
| US-6153742-A | SOLID PHASE SYNTHESIS PRODUCING ANTISENSE OLIGONUCLEOTIDES | UNIVERSITY OF BARCELONA (ES) | 2000-11-28 | — | — | US | claimed |
| WO-2000001711-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2000-01-13 | — | — | WO | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| US-5874568-A | CAN BE USED IN STUDIES FOR ELUCIDATING THE MECHANISMS OF MUTATIONS AND REPAIR OF DNA, ALSO USEFUL AS A REAGENT FOR CLINICAL TESTS, SUCH AS PRODUCTION OF ANTIBODIES DETECTING DAMAGED DNA. | BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE (JP) | 1999-02-23 | — | — | US | claimed |
| US-5756707-A | REACTING A PARTIALLY PROTECTED CYTOSINE RIBONUCLEOSIDE WITH A HYDROCARBON HALIDE IN THE PRESENCE OF A METAL SALT CATALYST AND A BASE | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1998-05-26 | — | — | US | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| EP-0787740-A2 | Coupling unit of (6-4)photoproduct, process for preparing the same, process for preparing oligonucleotide containing (6-4) photoproduct by using the same and process for preparing DNA containing (6-4) photoproduct by using the same | Biomolecular Engineering Research Institute (JP) | 1997-08-06 | — | — | EP | claimed |
| WO-1996018638-A2 | 2'-O-DERIVATIZED PYRIMIDINE RIBONUCLEOSIDES AND METHODS OF PRODUCTION | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1996-06-20 | — | — | WO | claimed |
| US-4178445-A | 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275793-A1 | Chemical RNA Synthesis Method | NSUN3, POLR2E, POLR2H | ATM 3698/4885L3MBTL1 375/4885MTNR1A 3393/4885 |
| US-20090047712-A1 | Chemically cleavable phosphoramidite linkers | CPSF6, RNGTT, CPSF1 | ATM 3431/4885L3MBTL1 221/4885MTNR1A 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.